Although peptide radionuclide therapy (PRRT) using a somatostatin analog (SSA) radiolabeled with a beta- emitter: [177Lu] Lu-DOTATATE has shown a good clinical efficacy in neuroendocrine tumors (NETs), most of the patients only achieved tumoral stabilization and rare but severe long-term hematological toxicities have been reported. One of the promising options to improve PRRT is targeted alpha therapy. It is therefore essential to propose animal models that can mimic systemic spread disease, especially microscopic disease such as early stage of NET liver metastases to explore targeted alpha therapy. Herein,we report the evaluation of efficacy and toxicity of [225Ac]Ac-DOTATOC in an original preclinical murine model simulating the development of well-characterized liver metastases of pancreatic NETs with SSTR overexpression.
LUGAT Alexandre;
CHOUIN N;
CHOCTEAU Florian;
ESNAULT Mathilde;
MARIONNEAU-LAMBOT S;
GOUARD S.;
FRAMPAS Eric;
FAIVRE-CHAUVET Alain;
BOURGEOIS Mickaël;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
CHEREL M.;
KRAEBER BODÉRÉ F;
ANSQUER Catherine;
GASCHET J;
2025-01-20
SPRINGER VERLAG
JRC138955
1619-7089 (online),
https://link.springer.com/article/10.1007/s00259-024-06918-0,
https://publications.jrc.ec.europa.eu/repository/handle/JRC138955,
10.1007/s00259-024-06918-0 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
